<\/p>\n
An overview of the AHA\/ACC\/ESC\/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).<\/em><\/p>\n Heart failure (HF) remains one of the leading causes of morbidity, mortality, and healthcare utilization worldwide. Despite significant advances in diagnosis and treatment, inconsistencies in the definition and classification of heart failure have posed challenges for clinical research, patient stratification, and personalized therapeutic decision-making.<\/p>\n To address these issues, the American Heart Association (AHA), American College of Cardiology (ACC), European Society of Cardiology (ESC), and World Heart Federation (WHF)<\/strong> have jointly published the Second Universal Definition of Heart Failure (2026)<\/strong>. This updated consensus provides a standardized framework for heart failure diagnosis while introducing several paradigm shifts that reflect contemporary evidence and the evolution of precision cardiovascular medicine.<\/p>\n Below are the most clinically relevant updates for healthcare professionals.<\/p>\n Historically, heart failure has been categorized according to fixed left ventricular ejection fraction (LVEF) thresholds. Although widely adopted, rigid LVEF cutoffs may fail to capture the continuous spectrum of ventricular function and may underestimate treatment benefits in certain patient populations.<\/p>\n The 2026 Universal Definition adopts a more clinically relevant phenotype-based approach by recognizing three major categories:<\/p>\n Rather than focusing solely on numerical LVEF values, the updated framework encourages clinicians to integrate cardiac function, disease trajectory, and clinical presentation into therapeutic decision-making. This approach also supports the use of evidence-based therapies in patients who may previously have fallen outside traditional LVEF thresholds.<\/p>\n The updated consensus emphasizes that heart failure is not a static disease but a dynamic syndrome with evolving structural, functional, and clinical characteristics.<\/p>\n Three distinct disease trajectories are now recognized:<\/p>\n Patients demonstrate a clinically meaningful increase in LVEF (\u226510 percentage points, reaching >40%) following treatment while residual structural or functional abnormalities may remain.<\/p>\n Patients achieve normalized ventricular function, minimal symptoms, and stable biomarkers. However, underlying disease processes persist, and recurrence remains possible.<\/p>\n A limited proportion of patients experience sustained normalization of cardiac structure, ventricular function, biomarkers, and clinical status over time.<\/p>\n Importantly, improvement in LVEF should not be considered synonymous with cure. Patients with HFimpEF continue to require guideline-directed medical therapy (GDMT) and long-term monitoring because relapse of ventricular dysfunction may occur.<\/p>\n Previous classifications frequently divided heart failure into ischemic and non-ischemic etiologies. While useful, this simplified approach does not adequately reflect the growing understanding of diverse cardiomyopathies and disease mechanisms.<\/p>\n The 2026 consensus introduces a comprehensive etiological framework that includes:<\/p>\n Earlier identification of the underlying etiology facilitates targeted therapeutic strategies and supports a precision medicine approach that extends beyond conventional heart failure management.<\/p>\n The document maintains the traditional four-stage heart failure continuum (Stages A\u2013D) while reinforcing the concept of Pre-Heart Failure (Stage B)<\/strong> as a critical window for intervention.<\/p>\n Among patients with diabetes, obesity, chronic kidney disease, or multiple cardiovascular risk factors, contemporary therapies have demonstrated the potential to reduce the incidence of new-onset heart failure.<\/p>\n Evidence supporting preventive strategies includes:<\/p>\n These developments illustrate the ongoing transition from treating established heart failure toward preventing disease progression across the cardiometabolic continuum.<\/p>\n For the first time, the consensus also explicitly recognizes the influence of social determinants of health (SDOH)<\/strong>\u2014including socioeconomic status, education, and healthcare accessibility\u2014on heart failure incidence and clinical outcomes.<\/p>\n To improve consistency across clinical practice and research, the consensus differentiates two frequently used clinical terms.<\/p>\n Progressive deterioration of symptoms, functional capacity, biomarkers (such as BNP or NT-proBNP), or cardiac structure in patients with established heart failure, regardless of hospitalization status.<\/p>\n Clinical deterioration requiring intensification of therapy, including escalation of diuretics, initiation of additional pharmacologic treatment, or advanced supportive interventions.<\/p>\n The distinction facilitates more accurate patient assessment and standardized reporting across clinical studies.<\/p>\n The Second Universal Definition of Heart Failure (2026)<\/strong> represents an important milestone in the evolution of heart failure care.<\/p>\n Major updates include:<\/p>\n Collectively, these updates strengthen the foundation for personalized heart failure management and support the integration of contemporary evidence-based therapies into routine clinical practice.<\/p>\n
\n<\/div>\n1. A More Flexible Classification of Left Ventricular Ejection Fraction (LVEF)<\/h6>\n
\n
\n<\/div>\n2. Recognizing Heart Failure as a Dynamic Clinical Syndrome<\/h6>\n
Improvement<\/h6>\n
Remission<\/h6>\n
Recovery<\/h6>\n
Clinical Perspective<\/h6>\n
\n<\/div>\n3. Expanding Etiological Classification to Enable Precision Medicine<\/h6>\n
\n
\n<\/div>\n4. Earlier Prevention Through Cardiometabolic Risk Management<\/h6>\n
\n
\n<\/div>\n5. Clarifying the Definitions of Worsening and Decompensated Heart Failure<\/h6>\n
Worsening Heart Failure<\/h6>\n
Decompensated Heart Failure<\/h6>\n
\n<\/div>\nKey Clinical Takeaways<\/h6>\n
\n
\n<\/div>\nReference<\/h6>\n